Traws Pharma, Inc. (TRAW)

Traws Pharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	0.23	0.23	0.23	0.23	0.23	2.18
Revenue Growth (YoY)	0%	0%	0%	-2.16%	-89.42%	77.77%
Gross Profit	0.23	0.23	0.23	0.23	0.23	2.18
Selling, General & Admin	10.34	9.09	8.45	9.43	8.33	8.35
Research & Development	9.26	11.43	11.41	7.3	16.9	15.54
Operating Expenses	19.6	20.52	19.85	16.72	25.22	23.88
Operating Income	-19.37	-20.3	-19.63	-16.5	-24.99	-21.7
Other Expense / Income	-1.22	-1.35	-0.66	-0.33	0.16	-0.21
Pretax Income	-18.16	-18.95	-18.96	-16.16	-25.15	-21.49
Income Tax	0	0	0	0	0	0.01
Net Income	-18.16	-18.95	-18.96	-16.16	-25.16	-21.5
Shares Outstanding (Basic)	21	21	21	17	12	1
Shares Outstanding (Diluted)	21	21	21	17	12	1
Shares Change	0.40%	0.39%	24.22%	45.08%	1109.89%	248.79%
EPS (Basic)	-0.87	-0.90	-0.91	-0.96	-2.17	-22.35
EPS (Diluted)	-0.87	-0.90	-0.91	-0.96	-2.17	-22.35
Free Cash Flow	-17.81	-17.95	-16.29	-19.49	-23.09	-20.89
Free Cash Flow Per Share	-0.85	-0.85	-0.78	-1.16	-1.99	-21.78
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-8572.12%	-8981.42%	-8684.51%	-7299.12%	-10819.48%	-994.00%
Profit Margin	-8033.63%	-8384.07%	-8391.15%	-7151.77%	-10890.48%	-985.02%
Free Cash Flow Margin	-7881.86%	-7940.71%	-7209.73%	-8622.57%	-9995.67%	-956.76%
EBITDA	-18.14	-18.93	-18.95	-16.15	-25.14	-21.48
EBITDA Margin	-8026.11%	-8376.99%	-8384.96%	-7145.58%	-10883.12%	-983.92%
Depreciation & Amortization	0.02	0.02	0.01	0.01	0.01	0.01
EBIT	-18.16	-18.95	-18.96	-16.16	-25.15	-21.49
EBIT Margin	-8033.63%	-8384.07%	-8391.15%	-7151.77%	-10888.74%	-984.56%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).